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1. Introduction
The At Risk Mental State (ARMS) construct was introduced two
decades ago, in 1996 [1], to allow identiﬁcation of subjects at clinical
high-risk for psychosis before full symptoms manifest. Subjects with
suspected psychosis risk are usually referred to specialized services,
where they undergo a speciﬁc psychometric assessment, such as the
Comprehensive Assessment of At Risk Mental State (CAARMS)
[1]. Upon completion of this assessment by expert and trained
clinicians, referred subjects are assigned a status of being at risk
(ARMS+) or not at risk (ARMS) for psychosis [2]. Focused
interventions are offered to those deemed ARMS+, in the light of
their enhanced risk of developing psychosis [3]. Conversely, ARMS
subjects are usually discharged from these services and referred to
other teams or to general practitioners [4]. Since its inception, the
ARMS construct has gained substantial traction to the point that
specialist ARMS provision has been recognized as an important
component of clinical services for early psychosis intervention [5,6]
(e.g. NICE guidelines [7]; recent NHS England Access and Waiting
Time [AWT] standard [5], DSM-5 diagnostic manual) [8].
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A B S T R A C T
Background: The long-term clinical validity of the At Risk Mental State (ARMS) for the prediction of non-
psychotic mental disorders is unknown.
Methods: Clinical register-based cohort study including all non-psychotic individuals assessed by the
Outreach And Support in South London (OASIS) service (2002–2015). The primary outcome was risk of
developing any mental disorder (psychotic or non-psychotic). Analyses included Cox proportional
hazard models, Kaplan–Meier survival/failure function and C statistics.
Results: A total of 710 subjects were included. A total of 411 subjects were at risk (ARMS+) and 299 not at
risk (ARMS). Relative to ARMS, the ARMS+ was associated with an increased risk (HR = 4.825) of
developing psychotic disorders, and a reduced risk (HR = 0.545) of developing non-psychotic disorders
(mainly personality disorders). At 6-year, the ARMS designation retained high sensitivity (0.873) but
only modest speciﬁcity (0.456) for the prediction of psychosis onset (AUC 0.68). The brief and limited
intermittent psychotic symptoms (BLIPS) subgroup had a higher risk of developing psychosis, and a
lower risk of developing non-psychotic disorders as compared to the attenuated psychotic symptoms
(APS) subgroup (P < 0.001).
Conclusions: In the long-term, the ARMS speciﬁcally predicts the onset of psychotic disorders, with
modest accuracy, but not of non-psychotic disorders. Individuals meeting BLIPS criteria have distinct
clinical outcomes.
Signiﬁcant outcomes: In the long-term, the ARMS designation is still signiﬁcantly associated with an
increased risk of developing psychotic disorders but its prognostic accuracy is only modest. There is no
evidence that the ARMS is associated with an increased risk of developing non-psychotic mental disorders.
The BLIPS subgroup at lower risk of developing non-psychotic disorders compared to the APS subgroup.
Limitations: While incident diagnoses employed in this study are high in ecological validity they have not
been subjected to formal validation with research-based criteria.
C 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The broad prognostic validity of the ARMS designation is
indexed by its ability to improve the pretest risk (for details see [9])
of developing mental disorders in subjects referred to high-risk
services (i.e. in those later deemed ARMS+ or ARMS)
[10]. Conducting long-term studies on ARMS+ and ARMS cohorts
can be complicated due to subject attrition, particularly when
following ARMS individuals. In fact, beyond the original
validation study [11], no further large-scale studies have been
designed to directly address the long-term clinical validity of the
ARMS designation for psychosis prediction [2]. Our recent meta-
analysis showed that the three ARMS studies that are available
have reported only indirect data, including small samples [12,13]
or an incomplete follow-up of the ARMS group [14]. Furthermore,
the broad long-term clinical outcomes of the ARMS group remain
unknown. As a result, the speciﬁcity of the ARMS for the prediction
other non-psychotic mental disorders, is not yet fully established.
Recent clinical staging models [15] have suggested that ARMS+
subjects may be also at increased risk also for the development of
non-psychotic mental disorders. These concerns arise in part
because most ARMS+ subjects will not develop full psychosis
[16]. Whether the ARMS signposts speciﬁcally to risk for future
psychosis, or to nonspeciﬁc deterioration in mental health, is of
paramount relevance for both clinical and research perspectives.
The present study aims to address these gaps in the literature.
We used a large, real-world sample of subjects accessing a high-
risk service, with a long follow-up period, to investigate the long-
term clinical validity of the ARMS assessment. We ﬁrst reported
the pretest risk for the development of any mental disorder, to
account for the initial level of risk in this selected population. We
then investigated the long-term prognostic accuracy of the ARMS




We included all non-psychotic subjects assessed for suspicion
of psychosis risk by the Outreach and Support in South London
(OASIS) high-risk service, South London and the Maudsley NHS
Foundation Trust (SLaM) [17]. The OASIS is a specialised clinical
service for the assessment and treatment of ARMS individuals.
Established in 2001 and currently led by one of the authors of the
present study (PFP) it is one of the largest services of this type in
Europe. All help-seeking subjects referred to OASIS on suspicion of
psychosis risk in the period 1st January 2002 to 31st December
2015 were initially considered eligible. We then excluded those
who were referred but never assessed by the team, and those who
were already psychotic at baseline. The remaining sample was
therefore composed of all non-psychotic subjects undergoing a
CAARMS-based assessment at OASIS, as part of the standard care.
The details of the CAARMS assessment at OASIS are detailed in a
separate paper [18]. Upon completion of the assessment, these
subjects were assigned the status ARMS+ or ARMS. Details of the
speciﬁc care received at OASIS team have been described
elsewhere [19].
2.2. Study measures
The primary outcome of interest was the hazard ratio (HR) of
developing any ICD-10 non-organic mental disorders in ARMS+
subjects as compared to ARMS subjects (see supplementary data,
eMethod 1).
Time to diagnosis of a mental disorder was measured from the
date of the ARMS assessment conducted at the OASIS, censored at
1st March 2016.
Descriptive sociodemographic variables were: age [20], gender
[20], ethnicity [20] (black, white, Asian, Caribbean, mixed, other),
familial environment [21] (marital status: married, divorced or
separated, single, in a relationship), and socioeconomic status [22]
(index of multiple deprivation, IMD 2015 [23], see supplementary
data, eMethod 2). All sociodemographic variables were those
recorded closest to the time of ﬁrst referral to OASIS.
2.3. Procedure
Clinical register-based cohort study. Primary outcome and
sociodemographic variables were automatically extracted from
electronic medical records with the use of the Clinical Record
Interactive Search (CRIS) tool [24] (see supplementary data,
eMethod 3).
2.4. Statistical analysis
Sociodemographic characteristics of the ARMS+ vs. ARMS
samples were described by means and SDs for continuous
variables, and absolute and relative frequencies for categorical
variables. Baseline ARMS+ vs. ARMScharacteristics were com-
pared using Student’s t-tests and Chi2. The clinical validity of the
ARMS assessment was investigated with Cox proportional hazards
models (non-competing risk), evaluating the effects of ARMS status
(ARMS+ vs. ARMS) on the development of any incident mental
disorders (any mental disorders, psychotic disorders, non-psy-
chotic disorders) and time to development of these disorders, after
checking for proportional hazards assumption [25]. Incident
disorders were deﬁned as the emergence of an ICD-10 primary
diagnosis from the aforementioned groups, at any time during the
follow-up, when no primary diagnosis in that ICD-10 group was
present at baseline (in the ﬁrst three months following referral to
OASIS). We also described the impact of ARMS+ subgroups
(Attenuated Psychotic Symptoms [APS]; Genetic Risk and Deterio-
ration [GRD]; Brief and Limited Intermittent Psychotic Symptoms
[BLIPS]) vs. ARMS on the development of incident mental
disorders, psychotic disorders and non-psychotic disorders.
Subjects meeting multiple ARMS criteria were stratiﬁed for
symptom severity as previously suggested [16]: any BLIPS > APS
or APS + GRD > GRD alone. We further described the cumulative
incidence of the outcome of interest with Kaplan–Meier failure
function (1-survival) [26]. Clinical validity (apparent performance)
was determined with the C statistic (area under the curve [AUC]).
All analyses were conducted in STATA 13 (STATA Corp., TX, USA).
3. Results
3.1. Sociodemographic and clinical characteristics of the sample
From 2002 to 2015, a total of 1115 subjects were referred to the
OASIS clinic for ARMS assessment. Among them, 125 subjects did
not undergo the ARMS assessment and had no contact with the
OASIS service. An additional 280 subjects were already psychotic at
baseline (the clinical fate of these subjects is described elsewhere
[27]). A ﬁnal sample of 710 non-psychotic subjects who underwent
ARMS assessment was used in the analyses. The sample included
411 ARMS+ subjects and 299 ARMS subjects (Table 1). The
average age of the sample was 23 years (range 12–44), with 56%
males. Half of the sample was of white ethnicity, the vast majority
was single and the mean IMD score was 32%. There were no
signiﬁcant differences in sociodemographic characteristics be-
tween ARMS+ and ARMS, with the exception of ethnicity; there
were more ARMS+ subjects of black ethnicity as compared to
ARMS subjects. The mean follow-up time was of 1472 days (SD
1171 days).
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3.2. Pretest risk of developing any mental disorders in subjects
undergoing ARMS assessment
The pretest probability of developing any mental disorder in
the entire pool of subjects undergoing ARMS assessment
(n = 710, Fig. 1), indicated a 6-year cumulative incidence of
0.44 (95% CI: 0.395–0.494). Since the last failure was observed
at 2192 days/6.01 years, when 133 subjects were still at risk
(not censored), in the following analyses we report the
descriptive cumulative incidence of the failure functions at this
timepoint.
3.3. Long-term clinical validity of the At Risk Mental State
3.3.1. Prediction of any mental disorder
There were no signiﬁcant between-group differences in hazard
risks (HR = 0.979, Table 2). The 6-year cumulative incidence was
0.445 (95% CI: 0.387–0.507) in the ARMS+, and 0.431 (95% CI:
0.347–0.525) in the ARMS (supplementary data, eFigure 1). The
mean time to event in ARMS+ was 2979 days (95% CI: 2733–3225)
and in ARMS was 2584 (95% CI: 2299–3225).
3.3.2. Prediction of psychotic disorders
There were signiﬁcant between-group differences in hazard
risk, with higher risk of psychosis in the ARMS+ as compared to the
ARMS (HR = 4.83, Table 2). The 6-year cumulative incidence was
0.201 (95% CI: 0.161–0.250) in the ARMS+ and 0.042 (95% CI:
0.022–0.076) in the ARMS (Fig. 2). The mean time to event in
ARMS+ was 4124 days (95% CI: 3933–4315) and in ARMS was
3940 days (95% CI: 3847–4033).
Fig. 1. Cumulative incidence (Kaplan–Meier failure function) for pretest risk of
developing any mental disorders in subjects undergoing At Risk Mental State
(ARMS) assessment. The dotted line indicates the last event (failure) at 2192 days.
Table 1
Sociodemographic characteristics of subjects undergoing ARMS assessment at the OASIS clinic (n = 710).
ARMS+ (n = 411) ARMS (n = 299)
Mean SD Mean SD t P
Age (years) 23.04 5.6 23.21 5.05 0.401 0.689
Index of multiple deprivation (IMD) 31.48 0.412 32.55 0.497 1.661 0.097
Count % Count % X2 P
Gender
Males 229 0.56 170 0.57 0.091 0.763
Females 182 0.44 129 0.43
Ethnicity
Black 107 0.27 51 0.20 12.61 0.027
White 193 0.49 131 0.50
Asian 20 0.05 10 0.04
Caribbean 20 0.05 12 0.05
Mixed 18 0.05 16 0.06
Other 33 0.08 41 0.16
Marital status
Married 13 0.04 6 0.02 2.331 0.525
Divorced or separated 14 0.04 5 0.02
Single 325 0.90 225 0.93
In a relationship 10 0.02 7 0.03
ARMS: At Risk Mental State; OASIS: Outreach And Support in South London.
Table 2
Long-term clinical validity of the ARMS for the prediction of mental disorders. Cox proportional hazards analyses. Failure events were deﬁned as the emergence of an ICD-10
primary diagnosis from the different groups, at any time during the follow-up, when no primary diagnosis in that ICD-10 group was present at baseline.
Failure events Predictor n HR 95% CI P Se Sp AUC 95% CI
Any mental disorder ARMSa 595 0.979 0.734 1.304 0.884 0.644 0.401 0.525 0.485 0.567
Psychotic disorders ARMSa 710 4.825 2.484 9.371 < 0.001 0.873 0.456 0.678 0.624 0.701
Non-psychotic disorders (any) ARMSa 595 0.545 0.387 0.766 < 0.001 0.507 0.351 0.434 0.385 0.481
Substance use disorders ARMSa 698 0.821 0.219 3.064 0.769 0.556 0.421 0.488 0.315 0.661
Bipolar mood disorders ARMSa 705 1.689 0.327 8.719 0.531 0.714 0.421 0.568 0.386 0.749
Non-bipolar mood disorders ARMSa 669 0.778 0.426 1.424 0.416 0.558 0.415 0.487 0.409 0.562
Anxiety disorders ARMSa 680 0.798 0.447 1.430 0.449 0.575 0.406 0.490 0.416 0.564
Personality disorders ARMSa 696 0.179 0.066 0.483 0.001 0.217 0.404 0.311 0.226 0.389
Developmental disorders ARMSa 704 0.339 0.189 0.489 < 0.001 0.001 0.416 0.201 0.189 0.226
Disorders with childhood/adolescence onset ARMSa 707 1.361 0.249 7.441 0.722 0.667 0.423 0.545 0.337 0.752
Physiological syndromes ARMSa 707 0.696 0.043 11.138 0.798 0.500 0.419 0.459 0.001 0.951
ARMS: At Risk Mental State; na: not available; Se: sensitivity; Sp: speciﬁcity; AUC: area under the curve.
a ARMS+ vs. ARMS (base).
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At the 6-year timepoint, the ARMS assessment showed a very
good sensitivity (0.873, Table 2) but only a modest speciﬁcity
(0.456). This was reﬂected by a moderate negative likelihood ratio
(LR) of 0.276 and a small positive likelihood ratio (LR+) of 1.612
(for details on LR, LR+ and probabilistic prognostic reasoning in
ARMS see [9]), with a modest AUC (mean 0.68, 95% CI: 0.62–0.70).
3.3.3. Prediction of non-psychotic disorders
There were signiﬁcant between-group differences in hazard
risks between the ARMS+ and ARMS (HR = 0.545, Table 2), with
higher risk of non-psychotic disorders in the ARMS than in the
ARMS+ group. The 6-year cumulative incidence was 0.281 (95% CI:
0.226–0.347) in the ARMS+ and 0.404 (95% CI: 0.320–0.501) in the
ARMS (supplementary data, eFigure 2). The mean time to event in
ARMS+ was 3710 days (95% CI: 3473–3946), and in ARMS
2691 days (95% CI: 2404–2978).
3.3.4. Prediction of speciﬁc non-psychotic disorders
There were no signiﬁcant between-group differences in the
hazard risks for the development of bipolar mood disorders
(supplementary data, eFigure 3), non-bipolar mood disorders
(supplementary data, eFigure 4), anxiety disorders (supplementary
data, eFigure 5), substance use disorders, disorders with child-
hood/adolescence onset, or physiological syndromes (Table 2 and
supplementary data, eResults). Conversely, there was higher risk of
development of personality disorders (48% of the failures were
coded as ICD-10 F63 emotionally unstable personality disorders) in
the ARMS as compared to the ARMS+ group (HR = 0.179, Table 2).
The 6-year cumulative incidence was 0.022 (95% CI: 0.009–0.054)
in the ARMS+ and 0.095 (95% CI: 0.058–0.154) in the ARMS
(supplementary data, eFigure 6). There was also higher risk of
developing developmental disorders in the ARMS as compared to
the ARMS+ (HR = 0.339, Table 2) but there were only a very few
(n = 2) failures. The 6-year cumulative incidence was 0.019 (95%
CI: 0.004–0.090) in the ARMS, while there were no failures in the
ARMS+ subgroup.
3.3.5. ARMS subgroups and prediction of mental disorders
There were not enough cases in the GRD subgroup to allow
meaningful statistical analyses (n = 6). These subjects were
therefore discarded from the following analyses. When the APS
and BLIPS subgroups where compared with ARMS, there were no
signiﬁcant between-group differences in the risk of development
of any mental disorders (P = 0.892). However, there were signiﬁ-
cant differences in the risk of developing psychotic disorders
between the groups (P < 0.001). There were also signiﬁcant
between-group differences in the risk of developing non-psychotic
mental disorders (P < 0.001), with the lowest risk in the BLIPS
subgroup, the highest risk in the ARMS subgroup and the APS
subgroup in an intermediate position (Fig. 3).
4. Discussion
This study has the largest sample size and longest follow-up
period of any study that has investigated the real-world clinical
validity of the ARMS designation. In subjects undergoing ARMS
assessment, the 6-year pretest risk for the development of any
mental disorder was 0.44 and higher than in unselected samples.
At 6-year follow-up, the ARMS+ group was associated with a
ﬁvefold risk of developing psychosis as compared to the ARMS
group. In the long-term, the CAARMS retained very good sensitivity
but only modest speciﬁcity. The ARMS+ was associated with a
lower risk of developing non-psychotic disorders (mostly person-
ality disorders) relative to the ARMS. Among ARMS+ subgroups,
the BLIPS subgroup had a lower risk of developing non-psychotic
disorders than the APS subgroup.
To our knowledge, this is the ﬁrst study to investigate the risk of
developing any mental disorder (psychotic and non-psychotic) in
subjects undergoing and completing an ARMS assessment. Under-
standing whether the ARMS status delineates speciﬁc risk for
developing mental disorders necessarily relies upon the reporting of
incident rates of different classes of psychiatric disorders. Because
our database drew directly from real-world and real-time electronic
health records, we were able to track the incident diagnoses of all
ICD-10 non-organic mental disorders. This approach allowed us to
estimate the overall burden of risk of subjects referred to high-risk
services. We found that their overall pretest risk of developing any
mental disorder (i.e. before completion of the ARMS assessment)
accumulated to approximately 44% at 6 years. This value is higher
than the 6-year incidence of 27.84% (95% CI: 27.24%–28.44%
estimated from a previous study [28]) for any mental disorder in
primary care settings, consistent with ARMS subjects representing
selected help-seeking samples. These ﬁndings are in line with the
recently observed risk enrichment and increased vulnerability for
the development of mental disorders in subjects seeking help from
high-risk services [10]. Because the observe pretest risk enrichment
is substantial, pretest risk stratiﬁcation models have been recently
developed and validated by our group [29].
The CAARMS assessment then deﬁned the ARMS+ and ARMS
groups from this selected and help-seeking population. There was
Fig. 2. Cumulative incidence (Kaplan–Meier failure function) for the long-term risk
of development of psychotic disorders in At Risk Mental State (ARMS)+ (n = 411)
and ARMS (n = 299) subjects. LR+ 1.612, LR 0.276.
Fig. 3. Cumulative incidence (Kaplan–Meier failure function) for the long-term risk
of development of non-psychotic disorders in At Risk Mental State (ARMS)+ (APS)
(n = 299), ARMS+ (BLIPS) (n = 62) and ARMS (n = 228) subjects.
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no signiﬁcant difference in the overall 6-year cumulative incidence
of any mental disorders between ARMS+ (45%) and ARMS (43%)
(supplementary data, eFigure 1). However, there was an increased
risk for psychotic disorders in ARMS+ and an increased risk for non-
psychotic disorders in the ARMS.
We have thus replicated the earlier ﬁndings of the original
validation study [11] by conﬁrming that the ARMS+ was associated
with greater risk of developing psychotic disorders, even in the
longer term. The ARMS assessment retained a good ability to rule
out psychosis (as reﬂected by the high sensitivity, 0.873), but was
associated with an inadequate ability to rule in psychosis (as
reﬂected by the modest speciﬁcity, 0.456) (Fig. 2). Similarly, the LR
of 0.276 indexed a moderate [30] decrease of pretest probability for
psychosis following an ARMS designation, while the LR+ of
1.612 indexed only a slight [30] increase in pretest probability for
psychosis following an ARMS+ designation. These results indicate a
modest long-term prognostic accuracy (AUC 0.68) and the need to
speciﬁcally improve the ability to rule in subsequent psychosis,
while preserving the outstanding ability to rule it out. As the clinical
gain of testing positive at an ARMS assessment is modest, it is
therefore essential to use it in samples that are already risk enriched
such as those accessing mental health services [31]. The use of the
ARMS assessments outside clinical samples is likely to dilute the
pretest risk and consequently the transition rates to psychosis
[32]. Sequential testing with combinations of predictive models
deriving from clinical, neurocognitive and biological domains are
currently being investigated to overcome some of these caveats [33].
Conversely, the ARMS+ was not associated with a higher risk of
developing mental disorders other than psychosis, relative to the
ARMS (supplementary data, eFigure 2). Although the risk for non-
psychotic disorders was signiﬁcantly lower in the ARMS+ relative
to the ARMS, approximately 27% of ARMS+ developed a non-
psychotic disorder by the 6-year timepoint. This comes in addition
to the high baseline prevalence of non-psychotic comorbid
disorders [34], impaired functioning [35] and the persistence of
non-psychotic comorbid disorders over follow-up [36] in ARMS+
samples. Taken together, these results do not support the notion of
diagnostic pluripotentiality in the ARMS+. As a risk state speciﬁc
for psychosis, the possible outcomes speciﬁcally associated with
the ARMS+ designation may include onset of psychotic disorders,
remission or persistence of initial ARMS symptoms and variable
functional outcomes, but not an increased risk of emergence of
non-psychotic mental disorders.
We also speciﬁcally investigated the type of non-psychotic
disorders associated with an ARMS designation. We conﬁrmed the
ﬁndings of previous studies in clinical high-risk samples, reporting
no increased risk for bipolar mood disorders, non-bipolar mood
disorders or anxiety disorders [37]. Our 6-year 1.7% cumulative
incidence for bipolar disorders in the ARMS+ (supplementary data,
eFigure 3) matches (albeit at different timepoints) to the previous
1.9% reported in the NAPLS-1 cohort [37]. Similarly, our 6-year
11.4% cumulative incidence for anxiety disorders (supplementary
data, eFigure 5) in the ARMS+ is close to the 10.8% rate reported in
the PREDICT sample [37]. Conversely, our 6-year 10% cumulative
incidence of non-bipolar mood disorders (supplementary data,
eFigure 4) appeared higher than the rates reported in NAPLS-1
[37]. However, the comparability of these ﬁndings may be
problematic due to the different time-points, study designs
employed and the operational differences between the CAARMS
and the Structured Interview for Psychosis-Risk Syndromes (SIPS)
[38]. More importantly, the cumulative incidences of these non-
psychotic disorders in the ARMS+ are similar to the annualized
6-year rates estimated from studies conducted in general
community studies for bipolar disorders (0.08% estimated from
[28]), non-bipolar mood disorders (8.29% estimated from [39]) and
anxiety disorders (9.48% estimated from [40]). Moreover, the
cumulative incidence of these disorders in the ARMS+ was lower
than in population-based studies of young adults at high-risk of
bipolar [41], non-bipolar mood [42] and anxiety [43] disorders.
Overall, these ﬁndings suggest that the ARMS could not effectively
be used as a preventative paradigm to alter the course of these non-
psychotic disorders.
We have also shown, for the ﬁrst time, no differences between
ARMS+ and ARMS in risk for the development of substance use
disorders, disorders with childhood/adolescence onset or physio-
logical syndromes, and uncertain ﬁndings with respect to
developmental disorders (due to the rare events). Conversely,
we found that the ARMS group had an increased risk for the
development of personality disorders (supplementary data,
eFigure 6). The 6-year cumulative incidence of personality
disorders was high in the ARMS, at 9.5%. Unfortunately, it is
not possible to compare this incidence rate with that of the general
population because the latter is unknown. Studies in patients
admitted to psychiatric services have reported incidence rates of
ICD-10 personality disorders of 11% during a 12-year period [44]
(supplementary data, eDiscussion 1). Future studies may compare
risk of development of non-psychotic disorders between subjects
undergoing ARMS assessment and healthy controls.
We additionally explored the impact of the type of ARMS
subgroup on long-term clinical outcomes. We have previously
shown that relative to the APS subgroup, the BLIPS subgroup has a
greater risk of developing psychosis [16]. In previous publications,
we also demonstrated that risk of developing psychosis in BLIPS
cases is comparable to concurrent ICD-10 diagnoses traditionally
employed to describe brief psychotic episodes [45]. The current
ﬁndings provide further evidence for the distinctiveness of the
BLIPS subgroup as compared to the APS [45,46]. More speciﬁcally,
we found that the BLIPS were less likely to transition to non-
psychotic disorders, relative to the APS. The high speciﬁcity towards
psychosis, coupled with the low risk of development of non-
psychotic disorders, suggest that the BLIPS subgroup is composed of
psychotic subjects with an endophenotype of the disorder that is
characterized by short and remitting phases and may represent a
distinct clinical stage as compared to the APS subgroup [47].
The principal limitation of the current study is that we did not
employ a structured psychometric interview to ascertain the type
of incident diagnoses at follow-up. Therefore, while the incident
diagnoses are high in ecological validity (i.e. they represent real-
world clinical practice), they have not been subjected to formal
validation with research-based criteria. However, as previously
noted in these samples [37], the use of structured diagnostic
interviews can lead to selection of patient subsamples and
introduce additional biases. Furthermore, there is also meta-
analytical evidence indicating that for some psychotic categories,
administrative data recorded in clinical registers are generally
predictive of true diagnosis [48].
5. Conclusions
Subjects meeting ARMS criteria have a speciﬁc higher risk of
developing psychotic disorders, whilst they are not at increased risk
of developing other non-psychotic disorders. Among ARMS subjects,
those meeting the BLIPS criteria have a distinct clinical outcome.
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